Cockerell Dermatopathology: TRICARE Lab Claims and the Obligation to Repay

In the Cockerell Dermatopathology fraud settlement, the Dallas clinic agreed to pay $3,750,000 over allegations of medically unnecessary TRICARE testing and knowingly concealing an obligation to repay the government. The government alleged that an outside management company used the clinic’s laboratory license in exchange for a share of testing revenue. The alleged bargain gave the clinic a cut of testing revenue while the bill went to a program serving military families.

TRICARE serves service members, veterans and their families. The Justice Department’s settlement announcement describes both the alleged testing arrangement and the later repayment issue.

What Was the Cockerell Dermatopathology Arrangement?

The government alleged that Cockerell Dermatopathology’s owner knowingly permitted Progen, a laboratory management company, to use the clinic’s lab license to submit false claims for medically unnecessary tests. The alleged price was twenty percent of the net revenue from those tests. The claims went to federal health insurance programs, including TRICARE.

A share of net testing revenue connects the financial return to the business produced through the arrangement. For an insider who knows the management contract, the revenue statements or the billing operation, that connection may be more revealing than the title on the contract. We examine what each company contributed, what it received and how that matched the work behind the claims.

The government alleged in the CorePath Laboratories and Oncology San Antonio settlements that CorePath agreed to pay $115 for each biopsy referred by Oncology San Antonio and its physicians, whereas the Cockerell allegations concerned a share of net testing revenue for permission to use a laboratory license.

The license was central to the alleged bargain. Under the Clinical Laboratory Improvement Amendments, federal laboratory standards govern a laboratory’s permitted testing and quality systems. Whether a patient needed the test is a separate question. Cockerell’s case put both permission to use the license and the medical need behind the resulting claims in dispute.

Why Did the Repayment Obligation Matter?

The government alleged that the clinic and its owner knowingly avoided and concealed an obligation to repay the United States for false TRICARE claims. The allegation reached beyond submitting a false bill: the government also sought to recover money it said the clinic knowingly kept when it owed repayment.

For a laboratory insider, the distinction is practical. The original order and claim explain why a payer sent money. Later communications, accounting entries and repayment decisions can explain what the people running the business understood about keeping it. Someone who works on the second part may see a problem that is invisible in a test result.

What Did the Settlement Resolve?

The civil settlement covered the allegations about false TRICARE claims and the concealed repayment obligation together. The Justice Department announced it on August 23, 2022.

The agreement included $1,875,000 in restitution within the settlement total and called for payments over three and a half years. The clinic’s owner and principal physician would be liable if the clinic failed to make any of its payments.

What Evidence Is Needed to Prove Fraud?

For allegations involving a laboratory license, unnecessary testing and retained payments, the useful evidence connects permission to use the license with the orders, tests, claims, payments and decisions about repayment. Our work is to establish those connections with you, including who knew what and when.

The 1997 Laboratory Medicine article Model Plan Helps Laboratories Fight Fraud described requisition forms with space for a diagnosis code supporting the medical necessity of each test. It also discussed identifying the components of test profiles and monitoring standing orders for continued validity. Those details matter to someone who knows how a testing menu becomes an order: a profile contains individual tests, each with its own medical-necessity question.

The article also addressed returning overpayments discovered in an internal investigation. That makes its discussion relevant to both sides of Cockerell’s case: the reason for the original testing and what happened after money came in. The question for an insider is who understood the repayment problem and what the company did with that knowledge.

In an arrangement like the one alleged here, the management contract and revenue statements address another part of the story: who benefited from the testing and on what terms. The license, the order and the payment each tell you something different. An employee who understands how those records fit together may be able to explain a business arrangement that looks ordinary when each document is read alone.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know Who Used the License

If you know how an outside company used your laboratory’s license, shared its revenue or handled money owed back to a federal health care program, speak with our whistleblower experts about how the license was used. We build the case with you and bring in laboratory fraud whistleblower lawyers who understand healthcare billing, management agreements and overpayments. We stay at your side throughout, working to turn what you know into your strongest laboratory fraud whistleblower case.